.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A head-to-head meta-analysis compared Xpert MTB/RIF with the newer Xpert MTB/RIF Ultra assay for tuberculosis diagnosis. Across the included studies, Ultra showed higher pooled sensitivity than the earlier Xpert platform, while specificity was slightly lower. The improvement in sensitivity was particularly relevant in paucibacillary presentations, including forms of disease in which bacterial burden can be low. For practicing pulmonologists, this matters because a highly sensitive rapid molecular test can improve diagnostic confidence when smear microscopy is negative but the clinical suspicion of TB remains substantial. The trade-off is that a modest reduction in specificity means results must still be interpreted in the context of symptoms, imaging and epidemiologic risk. This publication fits strongly with NAPCON's focus on molecular diagnostics and TB programmatic care. It also illustrates why newer molecular platforms should be understood as part of a diagnostic algorithm rather than treated as isolated yes/no tests. The evidence supports using Ultra to improve detection in selected settings, while recognizing that specimen type and disease site continue to influence test performance and that culture and other investigations may still be required.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A head-to-head meta-analysis compared Xpert MTB/RIF with the newer Xpert MTB/RIF Ultra assay for tuberculosis diagnosis. Across the included studies, Ultra showed higher pooled sensitivity than the earlier Xpert platform, while specificity was slightly lower. The improvement in sensitivity was particularly relevant in paucibacillary presentations, including forms of disease in which bacterial burden can be low. For practicing pulmonologists, this matters because a highly sensitive rapid molecular test can improve diagnostic confidence when smear microscopy is negative but the clinical suspicion of TB remains substantial. The trade-off is that a modest reduction in specificity means results must still be interpreted in the context of symptoms, imaging and epidemiologic risk. This publication fits strongly with NAPCON's focus on molecular diagnostics and TB programmatic care. It also illustrates why newer molecular platforms should be understood as part of a diagnostic algorithm rather than treated as isolated yes/no tests. The evidence supports using Ultra to improve detection in selected settings, while recognizing that specimen type and disease site continue to influence test performance and that culture and other investigations may still be required.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
